{"id":40048,"date":"2025-08-26T11:05:08","date_gmt":"2025-08-26T03:05:08","guid":{"rendered":"https:\/\/flcube.com\/?p=40048"},"modified":"2025-08-26T11:05:09","modified_gmt":"2025-08-26T03:05:09","slug":"henlius-serplulimab-and-abbott-drive-robust-2025-financials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40048","title":{"rendered":"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Shanghai Henlius Biotech, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) released its 2025 first\u2011half financials, reporting a 2.7\u202f% year\u2011on\u2011year rise in total revenue to RMB\u202f2,819.5\u202fmillion. Gross profit climbed 10.5\u202f% to RMB\u202f2,199.2\u202fmillion, while operating cash flow surged 206.8\u202f% to RMB\u202f770.9\u202fmillion, underscoring the company\u2019s strong liquidity position.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>R&amp;D Investment and Cash Flow Dynamics<\/strong><br>The group allocated RMB\u202f995.4\u202fmillion to research and development\u2014an increase of 21.3\u202f%\u2014focusing on pre\u2011clinical development of differentiated molecules and the expansion of core innovation platforms. Despite the higher R&amp;D spend, operating cash flow remained solid, reflecting efficient commercialization of the existing product pipeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Global Product Portfolio Expands<\/strong><br>Henlius now boasts 6 approved products covering 25 indications, with market access in almost 60 territories. Four of these products enjoy multi\u2011market approvals, reinforcing the company\u2019s international footprint. In the first half of 2025, global product revenue exceeded RMB\u202f2.5568\u202fbillion, up 3.1\u202f% YoY.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Serplulimab Drives Overseas Revenue Growth<\/strong><br>The PD\u20111 antibody Serplulimab (trade names HANSIZHUANG in China, Hetronifly in Europe) generated RMB\u202f597.7\u202fmillion in worldwide sales, reflecting a sharp uptick in international uptake. Meanwhile, the breast\u2011cancer biosimilar HANQUYOU (trademarks HERCESSI in the U.S. and Zercepac in Europe) delivered RMB\u202f1.4442\u202fbillion, cementing Henlius\u2019 leadership in the oncology biosimilar segment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Outlook for 2025 and Beyond<\/strong><br>With overseas sales volumes accelerating, the company projects significant growth in foreign\u2011market revenue and profitability for the full 2025 year, with momentum likely to carry into 2026. Cash inflows from business\u2011development agreements topped RMB\u202f1\u202fbillion, a 280\u202f% YoY jump, further strengthening the balance sheet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Strategic Collaborations Fuel Expansion<\/strong><br>Henlius has secured pivotal agreements to broaden its global reach:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Abbott<\/strong>: exclusive or semi\u2011exclusive licenses for four self\u2011developed biosimilars and one innovative biologic across 69 emerging markets, including Asia and Latin America.<\/li>\n\n\n\n<li><strong>Dr.\u202fReddy\u2019s<\/strong>: exclusive rights to HLX15, an anti\u2011CD38 monoclonal antibody, covering 43 countries in the U.S. and Europe.<\/li>\n\n\n\n<li><strong>Lotus<\/strong>: exclusive commercialization and semi\u2011exclusive development partnership for Serplulimab across multiple indications in South Korea.<\/li>\n\n\n\n<li><strong>Sandoz<\/strong>: exclusive commercialization rights for HLX13, a CTLA\u20114 inhibitor, in the U.S., EU, Japan, Canada, and Australia.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These alliances not only expand Henlius\u2019 product distribution network but also provide additional revenue streams and shared R&amp;D expertise.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/HKEX-EPS_20250825_11808263_0.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of HKEX-EPS_20250825_11808263_0.\"><\/object><a id=\"wp-block-file--media-a643ec5b-af6c-4cbc-b2b9-b650745c92fb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/HKEX-EPS_20250825_11808263_0.pdf\">HKEX-EPS_20250825_11808263_0<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/HKEX-EPS_20250825_11808263_0.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a643ec5b-af6c-4cbc-b2b9-b650745c92fb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first\u2011half financials, reporting a 2.7\u202f% year\u2011on\u2011year&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40051,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[30,27,270,862],"class_list":["post-40048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biotech","tag-finanical-reports","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius, Serplulimab and Abbott Drive Robust 2025 Financials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first\u2011half financials, reporting a 2.7\u202f% year\u2011on\u2011year rise in total revenue to RMB\u202f2,819.5\u202fmillion. Gross profit climbed 10.5\u202f% to RMB\u202f2,199.2\u202fmillion, while operating cash flow surged 206.8\u202f% to RMB\u202f770.9\u202fmillion, underscoring the company\u2019s strong liquidity position.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40048\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first\u2011half financials, reporting a 2.7\u202f% year\u2011on\u2011year rise in total revenue to RMB\u202f2,819.5\u202fmillion. Gross profit climbed 10.5\u202f% to RMB\u202f2,199.2\u202fmillion, while operating cash flow surged 206.8\u202f% to RMB\u202f770.9\u202fmillion, underscoring the company\u2019s strong liquidity position.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40048\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T03:05:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T03:05:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials\",\"datePublished\":\"2025-08-26T03:05:08+00:00\",\"dateModified\":\"2025-08-26T03:05:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048\"},\"wordCount\":371,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2602.webp\",\"keywords\":[\"Biotech\",\"Finanical Reports\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40048#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40048\",\"name\":\"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2602.webp\",\"datePublished\":\"2025-08-26T03:05:08+00:00\",\"dateModified\":\"2025-08-26T03:05:09+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first\u2011half financials, reporting a 2.7\u202f% year\u2011on\u2011year rise in total revenue to RMB\u202f2,819.5\u202fmillion. Gross profit climbed 10.5\u202f% to RMB\u202f2,199.2\u202fmillion, while operating cash flow surged 206.8\u202f% to RMB\u202f770.9\u202fmillion, underscoring the company\u2019s strong liquidity position.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40048\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40048#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first\u2011half financials, reporting a 2.7\u202f% year\u2011on\u2011year rise in total revenue to RMB\u202f2,819.5\u202fmillion. Gross profit climbed 10.5\u202f% to RMB\u202f2,199.2\u202fmillion, while operating cash flow surged 206.8\u202f% to RMB\u202f770.9\u202fmillion, underscoring the company\u2019s strong liquidity position.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40048","og_locale":"en_US","og_type":"article","og_title":"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials","og_description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first\u2011half financials, reporting a 2.7\u202f% year\u2011on\u2011year rise in total revenue to RMB\u202f2,819.5\u202fmillion. Gross profit climbed 10.5\u202f% to RMB\u202f2,199.2\u202fmillion, while operating cash flow surged 206.8\u202f% to RMB\u202f770.9\u202fmillion, underscoring the company\u2019s strong liquidity position.","og_url":"https:\/\/flcube.com\/?p=40048","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T03:05:08+00:00","article_modified_time":"2025-08-26T03:05:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40048#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40048"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials","datePublished":"2025-08-26T03:05:08+00:00","dateModified":"2025-08-26T03:05:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40048"},"wordCount":371,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40048#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2602.webp","keywords":["Biotech","Finanical Reports","Henlius Biotech","HKG: 2696"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40048#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40048","url":"https:\/\/flcube.com\/?p=40048","name":"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40048#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40048#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2602.webp","datePublished":"2025-08-26T03:05:08+00:00","dateModified":"2025-08-26T03:05:09+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first\u2011half financials, reporting a 2.7\u202f% year\u2011on\u2011year rise in total revenue to RMB\u202f2,819.5\u202fmillion. Gross profit climbed 10.5\u202f% to RMB\u202f2,199.2\u202fmillion, while operating cash flow surged 206.8\u202f% to RMB\u202f770.9\u202fmillion, underscoring the company\u2019s strong liquidity position.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40048#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40048"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40048#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2602.webp","width":1080,"height":608,"caption":"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40048#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius, Serplulimab and Abbott Drive Robust 2025 Financials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40048"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40048\/revisions"}],"predecessor-version":[{"id":40052,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40048\/revisions\/40052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40051"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}